07:00 , Oct 6, 2008 |  BC Week In Review  |  Company News

bioMerieux, ProteoSys deal

ProteoSys granted bioMerieux semi-exclusive, worldwide rights to IP covering the biomarker annexin A3 (ANXA3) to develop a diagnostic for prostate cancer. ProteoSys will receive an undisclosed upfront payment and is eligible for milestones and royalties....